Inicio › Mieloma múltiple › Florida
Ensayos clínicos de Mieloma múltiple en Florida
54 estudios sobre Mieloma múltiple buscan participantes en Florida.
Ciudades en Florida
- Miami22 estudios
- Jacksonville19 estudios
- Tampa15 estudios
- Kendall7 estudios
- Deerfield Beach6 estudios
- Hollywood6 estudios
- Plantation5 estudios
- Coral Springs5 estudios
- Fort Lauderdale3 estudios
- Pembroke Pines3 estudios
Texto oficial del estudio (inglés)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach
- Sylvester Comprehensive Cancer Center- Doral, Doral
- y 12 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06152575At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- Mayo Clinic in Florida, Jacksonville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05969860A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Moffitt Cancer Center, Tampa
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Memorial Healthcare System, Hollywood
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando
- Cleveland Clinic Florida, Weston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Florida Cancer Specialists & Research Institute, Fort Myers
- Mayo Clinic Jacksonville, Jacksonville
- University of Miami Hospital, Miami
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Memorial Healthcare System, Hollywood
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Florida, Jacksonville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Miami, Miami
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07280013A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Baptist MD Anderson Cancer Center, Jacksonville
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06615479Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Comprehensive Hematology Oncology, St. Petersburg
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT07609940A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
- University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach
- y 8 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT05623020Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Moffitt Cancer Center, Tampa
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06465316Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Moffitt Cancer Center - McKinley Drive, Tampa
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Miami, Miami
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Mayo Clinic Hospital - Florida, Jacksonville
- University of Miami Don Soffer Clinical Research Center, Miami
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Jacksonville
- Research Site, Tampa
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Moffitt Cancer Center /ID# 279068, Tampa
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT07409246A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Moffitt Cancer Center /ID# 272628, Tampa
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06892522A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Tampa
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07681596Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- SSAK Partners, Coral Springs
- Mayo Clinic - Jacksonville, Jacksonville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Tampa
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
- Miami Cancer Institute at Baptist Health, Inc., Miami
- Moffitt Cancer Center, Tampa
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 102, St. Petersburg
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07582432Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Florida, Jacksonville
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06630104The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07285044A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Tampa
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Jacksonville, Jacksonville
- Memorial Cancer Institute, Pembroke Pines
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Cancer Specialists of North Florida, Jacksonville
- D&H National Research Center, Margate
- Ocala Oncology Center, Ocala
- y 2 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Miami/Sylvester Cancer Institute - Aventura, Aventura
- University of Miami/Sylvester Cancer Institute - Lennar, Coral Gables
- University of Miami/Sylvester Cancer Institute - Deerfield Beach, Deerfield Beach
- y 8 más
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
- University of Miami, Miami
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT06997081Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Florida, Jacksonville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06375044A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Moffitt Cancer Center, Tampa
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07075185A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Fort Myers
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07227311A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Sylvester Comprehensive Cancer Center - Aventura, Aventura
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables
- Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs
- y 6 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT05020236Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Holy Cross Hospital, Fort Lauderdale
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Pembroke Pines
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT05714839IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
- University of Miami, Miami
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06376526Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Coral Gables
- Research Site, Tampa
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT06121843Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
- Mayo Clinic in Florida, Jacksonville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 jul 2026 · NCT05847569De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.